Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 123, Issue 18
May 1 2014
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
FDG/PET in CLL today
Clinical Trials & Observations
Stefano Molica
View Articletitled, FDG/PET in CLL today
INSIDE BLOOD COMMENTARY
Waldenström macroglobulinemia: genetics dictates clinical course
Clinical Trials & Observations
Georg Lenz
View Articletitled, Waldenström macroglobulinemia: genetics dictates clinical course
INSIDE BLOOD COMMENTARY
Hallway gossip between Ras and PI3K pathways
Peter D. Emanuel
View Articletitled, Hallway gossip between Ras and PI3K pathways
INSIDE BLOOD COMMENTARY
Neutrophil energetics and oxygen sensing
Sarah R. Walmsley,Moira K.B. Whyte
View Articletitled, Neutrophil energetics and oxygen sensing
INSIDE BLOOD COMMENTARY
Regulators help new immigrants settle down?
Defu Zeng
View Articletitled, Regulators help new immigrants settle down?

BLOOD WORK

After the treated mole
Armin Rashidi,Elaine M. Majerus
View Articletitled, After the treated mole
Revision of the diagnosis of a case of hereditary hemolytic anemia by supravital staining
Pim van Dijken,Richard van Wijk
View Articletitled, Revision of the diagnosis of a case of hereditary hemolytic anemia by supravital staining

REVIEW ARTICLE

Emerging roles for platelets as immune and inflammatory cells
Clinical Trials & Observations
Craig N. Morrell,Angela A. Aggrey,Lesley M. Chapman,Kristina L. Modjeski
View Articletitled, Emerging roles for platelets as immune and inflammatory cells
Thrombosis: tangled up in NETs
Kimberly Martinod,Denisa D. Wagner
View Articletitled, Thrombosis: tangled up in NETs

HOW I TREAT

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia
Miguel A. Sanz,Pau Montesinos
View Articletitled, How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

CLINICAL TRIALS AND OBSERVATIONS

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia
Clinical Trials & Observations
Lorenzo Falchi,Michael J. Keating,Edith M. Marom,Mylene T. Truong,Ellen J. Schlette,Rachel L. Sargent,Long Trinh,Xuemei Wang,Susan C. Smith,Nitin Jain,Zeev Estrov,Susan O’Brien,William G. Wierda,Susan Lerner,Alessandra Ferrajoli
View Articletitled, Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia
Clinical Trials & Observations
Steven P. Treon,Yang Cao,Lian Xu,Guang Yang,Xia Liu,Zachary R. Hunter
View Articletitled, Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia

IMMUNOBIOLOGY

Image-guided intrathymic injection of multipotent stem cells supports lifelong T-cell immunity and facilitates targeted immunotherapy
Andrea Z. Tuckett,Raymond H. Thornton,Yusuke Shono,Odette M. Smith,Emily R. Levy,Fabiana M. Kreines,Marcel R. M. van den Brink,Johannes L. Zakrzewski
View Articletitled, Image-guided intrathymic injection of multipotent stem cells supports lifelong T-cell immunity and facilitates targeted immunotherapy
Supplemental data

LYMPHOID NEOPLASIA

Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity
Rogier W. Rooswinkel,Bert van de Kooij,Evert de Vries,Madelon Paauwe,Rens Braster,Marcel Verheij,Jannie Borst
View Articletitled, Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity
Supplemental data

MYELOID NEOPLASIA

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML
Sophia Adamia,Michal Bar-Natan,Benjamin Haibe-Kains,Patrick M. Pilarski,Christian Bach,Samuel Pevzner,Teresa Calimeri,Herve Avet-Loiseau,Laurence Lode,Sigitas Verselis,Edward A. Fox,Ilene Galinsky,Steven Mathews,Ibiayi Dagogo-Jack,Martha Wadleigh,David P. Steensma,Gabriela Motyckova,Daniel J. Deangelo,John Quackenbush,Daniel G. Tenen,Richard M. Stone,James D. Griffin
View Articletitled, <em>NOTCH2</em> and <em>FLT3</em> gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML
Supplemental data
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells
Amy M. Cook,Liang Li,Yinwei Ho,Allen Lin,Ling Li,Anthony Stein,Stephen Forman,Danilo Perrotti,Richard Jove,Ravi Bhatia
View Articletitled, Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells
Supplemental data
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML
Brief Report
Charles B Goodwin,Xing Jun Li,Raghuveer S. Mali,Gordon Chan,Michelle Kang,Ziyue Liu,Bart Vanhaesebroeck,Benjamin G. Neel,Mignon L. Loh,Brian J. Lannutti,Reuben Kapur,Rebecca J. Chan
View Articletitled, PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib
Hyun Sik Jun,David A. Weinstein,Young Mok Lee,Brian C. Mansfield,Janice Y. Chou
View Articletitled, Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib

PLATELETS AND THROMBOPOIESIS

Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation
Eric Boilard,Guillaume Paré,Matthieu Rousseau,Nathalie Cloutier,Isabelle Dubuc,Tania Lévesque,Pierre Borgeat,Louis Flamand
View Articletitled, Influenza virus H<sub>1</sub>N<sub>1</sub> activates platelets through FcγRIIA signaling and thrombin generation
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation
Nayra Cardenes,Catherine Corey,Lisa Geary,Shilpa Jain,Sergey Zharikov,Suchitra Barge,Enrico M. Novelli,Sruti Shiva
View Articletitled, Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation
Supplemental data
Glycophorin C (CD236R) mediates vivax malaria parasite rosetting to normocytes
e-blood
Wenn-Chyau Lee,Benoit Malleret,Yee-Ling Lau,Marjorie Mauduit,Mun-Yik Fong,Jee Sun Cho,Rossarin Suwanarusk,Rou Zhang,Letusa Albrecht,Fabio T. M. Costa,Peter Preiser,Rose McGready,Laurent Renia,Francois Nosten,Bruce Russell
View Articletitled, Glycophorin C (CD236R) mediates vivax malaria parasite rosetting to normocytes
Supplemental data

THROMBOSIS AND HEMOSTASIS

Vessel wall BAMBI contributes to hemostasis and thrombus stability
Isabelle I. Salles-Crawley,James H. Monkman,Josefin Ahnström,David A. Lane,James T. B. Crawley
View Articletitled, Vessel wall BAMBI contributes to hemostasis and thrombus stability
Supplemental data

TRANSPLANTATION

Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment
Antonia M. S. Müller,Jessica Poyser,Natascha J. Küpper,Cassandra Burnett,Rose M. Ko,Holbrook E.K. Kohrt,Mareike Florek,Pei Zhang,Robert S. Negrin,Judith A. Shizuru
View Articletitled, Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment
Supplemental data

CORRESPONDENCE

The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature
Rebeca Manso,Margarita Sánchez-Beato,Silvia Monsalvo,Sagrario Gómez,Laura Cereceda,Pilar Llamas,Federico Rojo,Manuela Mollejo,Javier Menárguez,Javier Alves,Mónica García-Cosio,Miguel A. Piris,Socorro M. Rodríguez-Pinilla
View Articletitled, The <em>RHOA</em> G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature
Supplemental data
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
Clinical Trials & Observations
Mitul D. Gandhi,Andrew M. Evens,Timothy S. Fenske,Paul Hamlin,Bertrand Coiffier,Andreas Engert,Alison J. Moskowitz,Nilanjan Ghosh,Adam M. Petrich,Jon Lomasney,Amy Chadburn,Gary S. Wood,Katrin Salva,Beatrice Nardone,Steven M. Trifilio,Dennis W. Raisch,Dennis P. West,Leo I. Gordon,Jane N. Winter
View Articletitled, Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
Tet2-mutated myeloid progenitors possess aberrant in vitro self-renewal capacity
Hiroyoshi Kunimoto,Yumi Fukuchi,Masatoshi Sakurai,Keiyo Takubo,Shinichiro Okamoto,Hideaki Nakajima
View Articletitled, <em>Tet2-</em>mutated myeloid progenitors possess aberrant in vitro self-renewal capacity
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis
Shameem Mahmood,Julie Blundell,Anja Drebes,Philip N. Hawkins,Ashutosh D. Wechalekar
View Articletitled, Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis
Supplemental data

ERRATA

Diffner E, Beck D, Gudgin E, et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood. 2013;121(12):2289-2300.
View Articletitled, Diffner E, Beck D, Gudgin E, et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. <em>Blood.</em> 2013;121(12):2289-2300.
Purdue MP, Hofmann JN, Kemp TJ, et al. A prospective study of 67 serum immune and inflammation markers and risk of non–Hodgkin lymphoma. Blood. 2013;122(6):951-957.
View Articletitled, Purdue MP, Hofmann JN, Kemp TJ, et al. A prospective study of 67 serum immune and inflammation markers and risk of non–Hodgkin lymphoma. <em>Blood</em>. 2013;122(6):951-957.
Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013;121(26):5138-5144.
View Articletitled, Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <em>Blood</em>. 2013;121(26):5138-5144.
All Issues

Advertisement intended for health care professionals

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia
Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads
Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia
Leukemic myeloblasts with erythrophagocytosis

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals